Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
This study is comparing standard of care treatments for patients with CRE (Carbapenem-Resistant Enterobacteriaceae). Eligible patients will be randomized 2:1 to either the investigational antibiotic Carbavance or standard of care. Carbavance is a combination medication consisting of meropenem (an approved antibiotic) and RPX7009. Patients will be treated up to 14 days and followed up to 2 weeks after treatment completion.
Who may be Eligible  
Adults patients with know CRE infection; not pregnant or breastfeeding; agree to not become pregnant or father a child up to 30 days after study medication; agree to protocol defined birth control; normal maintenance labs as defined by protocol; not allergic to study medications; no co-morbid condition that will interfere with the study as defined by protocol; life expectancy greater than 72 hours; know or suspected endocarditis, meningitis, or osteomyelitis;
Start Date  
IRB Number  
Principal Investigator  
Polk, Christopher
Contact Name  

For More Information, Contact  Jessica  A, Kearney-Bryan
Phone:  (704) 355-0244  Fax:  (704) 446-7641  
Email:  Jessica.kearney-bryan@carolinashealhcare.org
Address:1350 S. Kings Drive, 3rd floor ID Clinic Charlotte, NC 28207